REVIEW article
Front. Endocrinol.
Sec. Diabetes: Molecular Mechanisms
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1630603
Recent advances in biomarkers for diabetes mellitus and tuberculosis comorbidity: a comprehensive review
Provisionally accepted
- 1Shenzhen Longhua District Central Hospital, Shenzhen, China
- 2Guangzhou Center for Disease Control and Prevention, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Diabetes mellitus (DM) and tuberculosis (TB) are significant global health challenges that complicate diagnosis, treatment, and management due to their interrelated nature. DM increases TB risk and worsens outcomes, highlighting the need for early detection and effective management. This review summarizes recent advancements in biomarkers for DM-TB comorbidity, including microbial, metabolic, immunological, inflammatory, clinical, and genetic markers. We identified 30 relevant studies, through a literature search using keywords related to DM, TB, and biomarkers. Key findings include specific gut microbiota genera and lipid mediators that show promise for early diagnosis and treatment. Immunological biomarkers like altered CD8+ T cells and NK cells provide insights into disease severity and treatment monitoring. Inflammatory markers such as elevated CRP, ferritin, and IL-6 reflect heightened inflammation and could guide treatment strategies. Clinical biomarkers, including serum CA-125 (sensitivity 88.14%, specificity 95.83%) and AUC/MIC ratios of anti-TB drugs (e.g., moxifloxacin ≥67; sensitivity 97.3%, specificity 90.0%), demonstrate high diagnostic accuracy. Future research should focus on validating these biomarkers across diverse populations and integrating them into clinical practice to enhance DM-TB management and contribute to global disease control efforts.
Keywords: Diabetes Mellitus, Tuberculosis, Comorbidity, biomarkers, Advancements
Received: 18 May 2025; Accepted: 30 Jul 2025.
Copyright: © 2025 Fang, Wu, Fang and Jie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ning Jie, Shenzhen Longhua District Central Hospital, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.